EP Fellows Curriculum: Antiarrhythmic Drug Therapy-EP Fellows Curriculum: Antiarrhythmic Drug Therapy

Video Transcription

Video Summary

In this video transcript, Dr. Stewie Patil discusses antiarrhythmic drug therapy. He primarily focuses on atrial fibrillation (AFib) and the indications for rhythm control. He discusses the different classes of antiarrhythmic drugs, specifically class 1 and class 3 drugs, which are known as the "real" antiarrhythmics. Dr. Patil explains the effects of these drugs on the action potential and highlights key points about each medication. He also mentions important drug-drug interactions and potential toxicities associated with these drugs, including thyroid toxicity, pulmonary toxicity, ocular toxicity, and neurologic toxicities. Dr. Patil emphasizes the need for careful monitoring and dosing adjustments based on a patient's renal function. He concludes by sharing guidelines for the use of antiarrhythmic drugs in patients with structural heart disease, such as heart failure and coronary disease, as well as hypertrophic cardiomyopathy. While the use of class 1C agents is generally not recommended, alternatives such as amiodarone, disopropylamide, sotalol, bicontilide, and dronesarone may be considered depending on the specific condition. Overall, Dr. Patil provides an overview of antiarrhythmic drug therapy with a focus on AFib treatment and considerations for different patient populations.

Keywords

antiarrhythmic drug therapy

atrial fibrillation

rhythm control

class 1 drugs

class 3 drugs

toxicities

renal function

structural heart disease

AFib treatment